PPBT vs. STSA, TPST, DERM, LABP, GNLX, ELDN, BTAI, AEON, LTRN, and CELU
Should you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Satsuma Pharmaceuticals (STSA), Tempest Therapeutics (TPST), Journey Medical (DERM), Landos Biopharma (LABP), Genelux (GNLX), Eledon Pharmaceuticals (ELDN), BioXcel Therapeutics (BTAI), AEON Biopharma (AEON), Lantern Pharma (LTRN), and Celularity (CELU). These companies are all part of the "pharmaceutical preparations" industry.
Purple Biotech (NASDAQ:PPBT) and Satsuma Pharmaceuticals (NASDAQ:STSA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability.
Satsuma Pharmaceuticals received 218 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 92.86% of users gave Purple Biotech an outperform vote while only 63.46% of users gave Satsuma Pharmaceuticals an outperform vote.
Purple Biotech has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Satsuma Pharmaceuticals has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500.
Purple Biotech's return on equity of -62.26% beat Satsuma Pharmaceuticals' return on equity.
9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 93.3% of Satsuma Pharmaceuticals shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 31.2% of Satsuma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Purple Biotech presently has a consensus target price of $9.00, indicating a potential upside of 1,014.55%. Given Purple Biotech's higher possible upside, research analysts plainly believe Purple Biotech is more favorable than Satsuma Pharmaceuticals.
In the previous week, Purple Biotech had 3 more articles in the media than Satsuma Pharmaceuticals. MarketBeat recorded 3 mentions for Purple Biotech and 0 mentions for Satsuma Pharmaceuticals. Purple Biotech's average media sentiment score of 0.20 beat Satsuma Pharmaceuticals' score of 0.00 indicating that Purple Biotech is being referred to more favorably in the media.
Purple Biotech is trading at a lower price-to-earnings ratio than Satsuma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Purple Biotech beats Satsuma Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
Get Purple Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Purple Biotech Competitors List
Related Companies and Tools
